On Monday, Shares of Matinas BioPharma Holdings Inc (NYSEMKT:MTNB) decreased -1.87% and closed at $1.57 after opening 1.65 with the overall traded volume of 306,174 shares. The company’s Market capitalization reached to $146.24 million, $91.40 million outstanding shares. Its low price was $1.56 and the highest price was $1.68.
Matinas BioPharma Holdings Inc (MTNB), a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid-based drug delivery platform called cochleate delivery technology. Its lead product candidate is MAT 2203, an orally-administered cochleate formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal infections.
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) decreased -1.30% and closed at $128.66 after opening 129.93 with the overall traded volume of 1.52 million shares. The company’s Market capitalization reached to $32.52 billion, $249.07 million outstanding shares. Its low price was $128.64 and the highest price was $130.36. The EPS is 0.71.
Vertex Pharmaceuticals Incorporated (VRTX) develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program.